Pharma — India Trademark Cases
454 decisions indexed
Page 14 of 16 · 454 total
Medley Pharmaceuticals Ltd. v.Khandelwal Laboratories Ltd.
The Bombay High Court dismissed the plaintiff's motion seeking an interim injunction in a passing off suit. The court found that the trade marks, including those with the prefix 'CEF,' are commonly used across the pharmaceutical industry. Given the prevalence of similar prefixes and suffixes derived from chemical compounds like Cefixime, the court held that the plaintiff failed to establish exclusivity or reputation for their mark, thus denying the injunction.
G.D. Searle Llc And Ors. v.Maiden Pharmaceuticals Ltd.
The Delhi High Court addressed applications for ad interim injunction concerning the anti-diarrhea drug LOMOTIL. The court found considerable merit in the plaintiffs' claims that the defendants' products (MICROTIL and MONOTIL) were deceptively similar to LOMOTIL, particularly regarding trade dress, packaging, and color scheme. However, instead of outright banning the defendant's trademarks, the court modified the existing injunctions. The defendants are permitted to market their products under their respective names, provided they significantly alter their product's visual appearance (trade dress) to avoid consumer confusion.
Torrent Pharmaceuticals Limited v.Reddy'S Laboratories Limited
Torrent Pharmaceuticals Limited filed an application for the trade mark 'DOPAMINE'. Reddy'S Laboratories Limited opposed this registration, arguing that 'DOPAMINE' was descriptively similar to their existing mark 'DOPAMET' and was a non-proprietary generic name for a chemical compound. The IPAB ultimately dismissed the appeal, agreeing with the opposition that the mark failed to meet the requirements of Section 9.
Milmet Oftho Industries & Ors. v.Allergan Inc.
The Supreme Court addressed a passing off dispute concerning the pharmaceutical mark 'OCUFLOX' between an Indian company and a multinational corporation. While acknowledging the global nature of medicine and the potential harm from confusion, the court emphasized that the ultimate test remains who was first in the market. The judgment directed the trial court to continue the injunction while expediting the suit for final determination based on evidence regarding prior use.
Pfizer Ireland Pharmaceuticals v.Intas Pharmaceuticals And Anr.
The Delhi High Court granted a temporary injunction in favor of Pfizer Ireland Pharmaceuticals against Intas Pharmaceuticals, finding that the defendants' use of the mark 'LIPICOR' was deceptively and confusingly similar to the plaintiff's globally reputed trademark 'LIPItor'. Despite the plaintiff not yet having entered the Indian market, the court recognized the trans-border reputation of LIPItor. The judgment emphasized the need for a stricter approach in pharmaceutical cases due to the potential disastrous effects on consumer health, thereby protecting the goodwill associated with the original brand.
Usv Limited v.Systopic Laboratories Limited
Usv Limited filed a suit for passing off against Systopic Laboratories Limited, alleging that the latter was deceptively using similar trade marks ('PIO-15'/'PIO-30') for medicinal preparations. The court examined issues of jurisdiction and whether the defendant's use caused confusion or deception.
Sun Pharmaceutical Industries Limited v.Wyeth Holdings Corporation And Anr.
The Bombay High Court dismissed the appeal filed by Sun Pharmaceutical Industries Limited against an interim order favoring Wyeth Holdings Corporation. The core dispute involved alleged infringement and passing off, where Wyeth held the registered trademark 'Pacitane' for anti-spasmodic preparations, and Sun used 'Parkitane'. The court found that due to the identical field of activity, common composition (Trihexylphenidyl), and high likelihood of consumer confusion, the appellants' use was fraudulent. Consequently, the court upheld the protective order granted to Wyeth.
Sanat Products Ltd. v.Glade Drugs And Nutraceuticals Pvt.
The Delhi High Court granted an interlocutory injunction in a passing off suit concerning pharmaceutical preparations. The plaintiff, Sanat Products Ltd., argued that the defendant's use of the mark 'REFORM' was deceptively and phonetically similar to its established trademark 'REFIRM', leading to potential confusion among consumers and medical practitioners. The court found that the similarity was likely to cause deception, especially given the nature of prescription drugs, and ruled that the balance of convenience favored granting the injunction to prevent irreparable harm to the plaintiff.
Sysmed Laboratories Pvt. Ltd. v.Panbross Pharmaceuticals
The Orissa High Court upheld a temporary injunction granted against Panbross Pharmaceuticals, finding that their product 'HYCAL FORTE' was deceptively similar to Sysmed Laboratories' established drug 'HICAL'. The court emphasized the high risk of consumer confusion in the pharmaceutical sector, where such errors can have disastrous health consequences. Given the phonetic and visual similarity between the marks, the High Court ruled that a prima facie case for passing off existed, thus dismissing the appeal.
Glaxo Group Ltd. v.Paun And Paum Chemicals
The Delhi High Court ruled in favor of Glaxo Group Ltd., finding that the defendant was infringing its trademarks 'Ostocalcium' and 'Ostocalcium Vet,' as well as engaging in passing off. The court found that the defendant's use of 'Oscal-Vet, D3' and the deceptively similar color scheme and get-up of its packaging material were likely to confuse the public. Consequently, a permanent injunction was granted, along with orders for the delivery up of infringing materials and rendition of accounts.
Usv Limited v.Systopic Laboratories Limited And Anr.
Usv Limited sought an injunction against Systopic Laboratories Limited for using trademarks (PIO, PIO-15, PIO-30) deemed deceptively similar to its own (PIOZ-15, PIOZ-30). The Madras High Court ultimately dismissed the application. The court held that the word 'PIO' is publici juris, meaning it describes the chemical ingredient and cannot be monopolized by a single party. Furthermore, the applicant failed to obtain leave to sue the first respondent and was found to have deliberately provided a false address for service, undermining its claim.
East African (I) Remedies Pvt. Ltd. v.Wallace Pharmaceuticals Ltd. And Anr.
The Delhi High Court dismissed the plaintiff's application seeking an ad interim injunction against trademark infringement. The court found that the plaintiff failed to establish a strong prima facie case, noting low historical sales figures and lack of evidence regarding goodwill. Conversely, the defendant demonstrated bona fide use, prior searches, and significant market presence with their product 'REVOX'. Consequently, the balance of convenience favored the defendant, who was allowed to continue manufacturing while being directed to deposit security for the plaintiff's interest.
Raptakos Brett & Co. Ltd. v.Cadila Laboratories Ltd.
Raptakos Brett & Co. Ltd. opposed the trademark application for NEOPLATIN by Cadila Laboratories Ltd., arguing that it was phonetically, visually, and structurally similar to their registered mark NEOPEPTINE. The Tribunal found an apparent conflict between the marks based on overall impression and sustained the opposition.
Khandelwal Laboratories Ltd. v.Fdc Limited
The Delhi High Court vacated an ex-parte injunction restraining the defendant from using the trade mark ZIFI, which was claimed to be deceptively similar to the plaintiff's CEFI. The court found that despite phonetic similarity, the defendant had a family of 'Z' trademarks and strong arguments regarding the weakness of pharmaceutical salt-derived marks. Considering the balance of convenience, the court ruled in favor of the defendant, allowing them to continue using their mark.
Cadila Healthcare Ltd. v.Swiss Pharma Pvt. Ltd. And Anr.
Cadila Healthcare Ltd. filed a suit alleging that Swiss Pharma Pvt. Ltd. was passing off its medicine SUPERDAC as Cadila's product SPARDAC due to deceptive similarity in the names. The trial court dismissed the suit, finding no evidence of deception or confusion. The Gujarat High Court upheld this decision, concluding that the two brand names were not deceptively similar.
Cadila Healthcare Ltd. v.Swiss Pharma Pvt. Ltd.
Cadila Healthcare Ltd. filed a suit alleging that Swiss Pharma Pvt. Ltd. was passing off its medicine, SUPERDAC, as Cadila's product, SPARDAC, due to deceptive similarity in the trade marks. The trial court dismissed the suit, finding no evidence of deception or confusion. The Gujarat High Court upheld this decision, concluding that the two names were not deceptively similar and there was no likelihood of consumer confusion.
Aviat Chemicals Pvt. Ltd. v.Magna Laboratories (Gujarat) Pvt. Ltd.
The plaintiffs filed a civil suit seeking permanent injunction against the defendant for infringing the registered trade mark MVI. The defendant challenged the validity of the registration and alleged that the plaintiff had been using the mark earlier, thus claiming prior user rights. The court ultimately found prima facie evidence of inordinate delay on the part of the plaintiffs.
Torrent Pharmaceuticals Ltd. v.The Wellcome Foundation Ltd.
The Gujarat High Court upheld the refusal of trademark registration for 'TROVIREX' filed by Torrent Pharmaceuticals Ltd. The court found that TROVIREX was deceptively similar to Wellcome Foundation Ltd.'s registered trademarks, ZOVIREX and ZOVIREX, particularly because both marks were used in relation to pharmaceutical products (similar goods). Citing established legal principles, the court concluded that allowing the registration would likely deceive consumers and cause confusion regarding the origin of the medicinal preparations.
Cadila Healthcare Limited v.Cadila Pharmaceuticals Limited
The dispute arose from a suit filed by Cadila Healthcare Limited against Cadila Pharmaceuticals Limited regarding the use of trade marks Falcigo and Falcitab for drugs treating cerebral malaria. The appellant claimed that the respondent's mark would cause passing off due to confusing similarity, especially since both were medicines of last resort.
Dr. Reddy's Laboratories Limited v.Manu Kosuri And Anr.
Dr. Reddy's Laboratories successfully sued defendants for cybersquatting and trademark infringement related to the domain name 'drreddyslab.com'. The court ruled that a domain name functions similarly to a trademark on the internet, granting it equal protection against passing off. Given the high similarity between the marks, the court found there was a clear likelihood of confusion among consumers. Consequently, the defendants were permanently restrained from using the infringing domain and were ordered to transfer 'drreddyslab.com' to Dr. Reddy's.
Cadila Healthcare Ltd. v.Union Of India (Uoi) And Ors.
Cadila Healthcare Ltd. challenged an order that rejected its plea to treat opposition proceedings against its 'CONAZOLE' trademark application as abandoned. The respondent (Uoi) argued that the opposing party had filed evidence, and Cadila failed to file its counter-evidence within the stipulated time. The court ultimately upheld the Registrar's decision to grant an extension of time, finding no infirmity in the order.
Wockherdt Ltd. v.Collector Of Central Excise
Wockherdt Ltd. appealed against an order classifying their product, Mannitol Injection B.P. 20% W/V, as a patent or proprietary medicine based on the design of its label. The company argued that simple labeling features like bars and color schemes do not automatically confer proprietary status unless they are registered trademarks or establish exclusive rights. The Tribunal sided with the appellant.
Mahesh Jayalal Dadhia & Another v.M/S. Thio Pharma & Others
The plaintiffs, members of the Dadhia family, sought an injunction restraining the defendants from manufacturing or trading pharmaceutical products bearing specific trademarks (BROSMIN, ACTIZYME, etc.). The dispute centered on ownership rights following a family arrangement and subsequent agreements regarding the joint business. The court found no merit in the Notice of Motion seeking injunction.
Wockhardt Limited v.Aristo Pharmaceuticals Limited
The Madras High Court ruled in favor of Wockhardt Limited, upholding the original ex parte injunction against Aristo Pharmaceuticals. The court found that despite the respondent's arguments regarding industry practice and generic terms, there was a likelihood of deception or confusion among unwary consumers due to the phonetic and visual similarity between the marks 'SPASMO-PROXYVON' and 'SPASMO-FLEXON'. This decision reinforces the principle that overall similarity is the key factor when assessing trademark infringement in the pharmaceutical sector.
Ciba-Geigy Ltd. v.Torrent Laboratories Ltd.
The Gujarat High Court addressed an opposition filed by Ciba-Geigy against Torrent Laboratories' trademark application for 'ULCIBAN.' The court ultimately ruled in favor of Torrent, finding that despite the inclusion of 'CIBA' within 'ULCIBAN,' there was no likelihood of confusion or deception among consumers. The judgment emphasized that when assessing similarity, the mark must be viewed as a whole, and phonetic/ocular resemblance is not automatically established simply because part of the word matches.
Indo-Pharma Pharmaceutical Works Ltd. v.Citadel Fine Pharmaceuticals Ltd.
The Madras High Court dismissed the appeal filed by Indo-Pharma Pharmaceutical Works Ltd. against Citadel Fine Pharmaceuticals Ltd., upholding the lower court's refusal to grant an interim injunction. The court found that despite both parties operating in the pharmaceutical sector, their products (allopathic syrup vs. Ayurvedic capsules) were distinct in form and character. Crucially, the court held that the prefix 'ENERJ' is a common, descriptive abbreviation of 'energy,' which cannot be monopolized as a trademark, while the suffixes 'JEX' and 'JASE' are phonetically and visually dissimilar enough to prevent consumer confusion.
Cadila Healthcare Ltd. v.Union Of India And Ors.
Cadila Healthcare Ltd. challenged an order that rejected its petition seeking to treat a trademark opposition (filed by M/s. Wockhordt Ltd.) as abandoned. The petitioner argued that the delay in filing evidence was prejudicial. The court examined the Registrar's power to grant extensions under Section 101 of the Act and held that such an extension is permissible, thus saving the opposition proceedings.
Torrent Pharmaceuticals Ltd. v.Union Of India (Uoi) And Ors.
Torrent Pharmaceuticals Ltd. appealed against the summary dismissal of its petition challenging the Registrar's action regarding a notice of opposition filed by Welcome Foundation Ltd. The core dispute revolved around whether the statutory provisions governing the submission of evidence during trademark opposition proceedings were mandatory or directory.
Winthrop Products Inc. v.Eupharma Laboratories Ltd.
The plaintiffs sought an injunction against defendants for infringing their registered trade mark, PANADOL, and passing off. The court found that the plaintiffs were the rightful proprietors of the trade mark and that the defendants lacked any vested right to use the name. Consequently, the defendants were prevented from using or passing off the trade mark.
T.T.K. Pharma Limited v.Ag. Robapharam
The respondent claimed ownership of the registered trademark "Ossopan" and filed a suit for injunction against the appellant/defendant. During the pendency of the suit, the respondent sought to amend the plaint to correct an apparent mistake regarding the description of specified goods, which was inconsistent with the registration certificate. The High Court upheld the amendment, rejecting the appeal filed by the defendant.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.